EXPEDITE: A Study of Remodulin Induction Followed by Orenitram Optimization to Treat Pulmonary Arterial Hypertension

NCT03497689 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

36

Enrollment

INDUSTRY

Sponsor class

Conditions

Pulmonary Arterial Hypertension

Interventions

DRUG: Intravenous/Subcutaneous Treprostinil; Oral Treprostinil

Sponsor

United Therapeutics